DATA: Generic competition affects drug prices
In 2001, Indian generic drug manufacturer Cipla announces that it will sell a generic copy of a triple-therapy antiretroviral (ARV) for US $350 per patient per year. This has an incredible impact, with the generated competition dramatically driving down the price of ARVs for developing countries while increasing the range of affordable options for national treatment programmes. This graph shows the lowest world price per patient per year of the fixed dose combination, stavudine + lamivudine + nevirapine.
Data Chart
May 2000 - August 2001
Timeline date:
2001-03-01
| Effects of generic drugs on brand drug prices | May | June | July | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brand prices ($) | 10439 | 10439 | 10439 | 10439 | 10439 | 931 | 931 | 931 | 931 | 931 | 712 | 712 | 712 |
| Generic prices ($) | 0 | 0 | 2767 | 800 | 800 | 800 | 800 | 800 | 350 | 295 | 295 | 295 | 295 |
Line